Pages

Monday, 11 November 2013

Shire Pharma - hunter and the hunted

Shire Pharmaceutical has been a perennial potential bid target in the UK market.  The last time I wrote about the stock a couple of months ago was after yet another write-up about bidders circling:

'One of Britain’s biggest drug makers has bolstered its bid defences amid fears of a £17bn takeover attempt by a big American rival. Shire, the FTSE 100 pharmaceutical giant, has hired Lazard to beef up its team of advisers as foreign predators prepare to pounce. It is thought Lazard’s appointment was prompted by an informal approach earlier this year from Bristol-Myers Squibb, which was rebuffed'

Shire is most famous for its ADHD treatments but is also active in treatments in neuroscience, rare diseases, gastrointestinal and  regenerative medicine.  They additionally have a good pipeline (one product in registration and nine in phase 3) and, as per numbers releases this year, they are still growing at a double digit rate and tilted those hopes up slightly in the last month.


Given the lack of growth at most of the large cap pharma companies, a c. US$25bn market cap entity could make a tasty/material acquisition target.  You can see the logic.

Today though, this story took a twist.  Shire is the company coming out and spending money on an acquisition.  As Seeking Alpha put it:

'Shire (SHPG) has agreed to acquire ViroPharma (VPHM) for $4.2B in a deal that will fit into the U.K. company's strategy of expanding its rare-disease portfolio and create a revenue base in the area of $2B...ViroPharma provides the treatment Cinryze for the prophylactic treatment of hereditary angioedema (HAE), which is when the deeper layers of the skin swell due to a build-up of fluid. Shire said Cinryze will compliment its Firazyr injection for acute HAE...Shire will pay $50 a share for ViroPharma, or a 27% premium on Friday's closing price of $39.38...Shire expects annual cost synergies of around $150M by 2015, and that the deal will immediately add to its earnings after completion'
And what was the immediate impact of the deal...well the London-listed shares went to another new high:
 
So the potentially hunted became the actual hunter.  Bulking up to stop someone else taking them over?  Or a rational and value-adding deal?
Well, unsurprisingly, the deal is accretive (everything almost always is at low interest rates):

And you can see the 'fit' too



In terms of financials, Shire is paying a pretty big price (c. x10 sales) for a company with sales (expected to be c. US$400m for FY13A) that have not gone anywhere fast for a few years. 

 
The market liked the complementary nature of the deal but - at a x16s prospective FY14e EV/ebit valuation pre-deal - Shire shares are getting very hot. 
The potential 'hunted' just got a bigger sticker price. 

No comments:

Post a Comment